USFDA accepts NextPoint Therapeutics’s IND for NPX887
With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express
Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.
The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,